South Korea Overhauls Pharma and Biotech Disclosure Rules Following Samchundang Controversy
South Korean financial authorities are overhauling disclosure regulations across the pharmaceutical and biotechnology sectors to curb exaggerated...
Biowatch
Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major technology-transfer agreement with Eli Lilly.
Ilyang Pharmaceutical Commits 17.6 Billion Won to China Comeback with Flagship Wonbi-D
Ilyang Pharmaceutical is mounting a fresh push into the Chinese market, reviving a business operation that had been...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.
Daewoong Pharmaceutical announced on July 23 that it has severed supply transactions with a domestic medical...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...